Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Sinobioway Biomedicine Co., Ltd. is a prominent Chinese biopharmaceutical company listed on the Shenzhen Stock Exchange (002581). The company specializes in the research, development, and manufacturing of biological drugs, including interferons, nerve growth factors, and vaccines, as well as pharmaceutical intermediates. Its flagship products include Anferon (recombinant human interferon alpha-2b) and Nobex (mouse nerve growth factor). Beyond its own product portfolio, the company provides CDMO and CRO services for the biopharmaceutical industry, supported by significant investments in large-scale biologics manufacturing facilities. It was formerly known as Zibo Wanchang Science & Technology and is a key member of the Sinobioway Group, which originated from Peking University.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Sinobioway Biopharma.